Biotech Stock Roundup: Ariad Down On Drug Pricing Tweet, Regeneron Study On Clinical Hold
October 19, 2016 at 15:27 PM EDT
Shares of Ariad declined 14.8% after Senator Bernie Sanders tweeted on the company’s price hike of leukemia drug Iclusig.
